We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Lifestyle Intervention for Diabetes and Weight Management in Psychosis (Healthy_LIFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01828931
Recruitment Status : Completed
First Posted : April 11, 2013
Last Update Posted : June 17, 2016
Canadian Diabetes Association
Information provided by (Responsible Party):
Margaret Hahn, Centre for Addiction and Mental Health

Brief Summary:
The rate of type-2 diabetes mellitus (T2DM) is at least 2-3 times higher in persons with psychotic illnesses than in the general population. Life expectancy of individuals with psychosis is also 20-25 years less than the general population, primarily due to premature onset of cardiovascular disease (CVD). Despite the high risk for T2DM and CVD, psychotic illness has been an exclusion criterion in all large-scale studies of diabetes prevention and management. We propose a 3-year randomized controlled trial examining the effectiveness of a lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity in overweight or obese individuals (N=150) suffering from both a psychotic illness and T2DM. Weight and glycemic control will be the primary outcome variables. It is hypothesized that a significant weight reduction and improvement in glycemic control will be found in those who receive the LI relative to those who do not.

Condition or disease Intervention/treatment
Type 2 Diabetes Mellitus Schizophrenia Schizoaffective Disorder Schizophreniform Disorder Bipolar I Disorder Substance-induced Psychosis Psychotic Disorders Major Depressive Disorder Behavioral: Lifestyle Intervention Other: Usual Care

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With Psychosis
Study Start Date : December 2012
Primary Completion Date : May 2015
Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Usual Care
Standard care provided via participants' family physicians, diabetes nurses, and psychiatrists.
Other: Usual Care
Care as usual
Experimental: Lifestyle Intervention
A lifestyle intervention based on the Look AHEAD study intervention, involving counselling related to dietary and physical activity habits.
Behavioral: Lifestyle Intervention
A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity

Primary Outcome Measures :
  1. Weight [ Time Frame: 52 weeks ]
  2. HbA1c levels [ Time Frame: 52 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Between the ages of 18 and 70 years (inclusive)
  2. DSM-IV-TR diagnosis of one of the psychotic disorders listed above
  3. Body Mass Index (BMI) > 25 kg/m2 at the time of enrollment
  4. Clearly documented diagnosis of type-2 diabetes mellitus or prediabetes
  5. Ability to provide informed consent
  6. No medical contraindication to participation in weight reduction / exercise program, determined in consultation with their primary care physician
  7. Female participants, of childbearing potential, using a medically accepted means of contraception

Exclusion Criteria:

  1. Inability to give informed consent
  2. Currently enrolled in a formal structured weight management program
  3. Currently being prescribed medication specifically for weight loss
  4. Participants with unstable or active cardiovascular illnesses (myocardial infarction, CHF, etc), active or end-stage renal disease, unstable thyroid disease, etc.
  5. Recurrent episodes of diabetic ketoacidosis, seizure or coma without warning or severe hypoglycemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01828931

Canada, Ontario
Centre for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1H4
Sponsors and Collaborators
Centre for Addiction and Mental Health
Canadian Diabetes Association
Principal Investigator: Margaret K Hahn, M.D. Centre for Addiction and Mental Health

Responsible Party: Margaret Hahn, Staff Psychiatrist, Centre for Addiction and Mental Health
ClinicalTrials.gov Identifier: NCT01828931     History of Changes
Other Study ID Numbers: 151/2012
First Posted: April 11, 2013    Key Record Dates
Last Update Posted: June 17, 2016
Last Verified: June 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Depressive Disorder
Depressive Disorder, Major
Psychotic Disorders
Mental Disorders
Shared Paranoid Disorder
Psychoses, Substance-Induced
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Schizophrenia Spectrum and Other Psychotic Disorders
Mood Disorders
Behavioral Symptoms
Chemically-Induced Disorders
Substance-Related Disorders